论文部分内容阅读
回顾性比较了两组用不同剂量的环胞菌素(CsA)和甲基强的松龙(MP)预防、治疗的异基因骨髓移植(BMT)后并发急性移植物抗宿主病(AGVHD)患者的生存期及复发率。第一组62例,中位年龄37岁。62例中急性淋巴细胞白血病(ALL)4例,急性粒细胞白血病(AML)16例,慢性粒细胞白血病(CML)20例,其他恶性血液病22例。患者接受“标准”方案即GsA1～3mg/kg·dⅣ,保持血浆浓度在150～200U/L预防GVHD,并发GVHD时,予MP2mg/kg·d治疗。第二组114例,中位年龄35岁,其中ALL26例,AML33例,CML27例,其他恶性血液病30例。患者接受增强方案:在未出现肾毒性时用CsA 5ng/kg·d Ⅳ(当血清
We retrospectively compared two groups of patients with acute graft-versus-host disease (AGVHD) after allogeneic bone marrow transplantation (BMT) treated with different doses of cyclosporin (CsA) and methylprednisolone (MP). The survival and recurrence rate. The first group of 62 patients, the median age of 37 years. Among 62 cases, 4 were acute lymphoblastic leukemia (ALL), 16 were acute myeloid leukemia (AML), 20 were chronic myeloid leukemia (CML), and 22 were hematological malignancies. The patient received a “standard” regimen of GsA 1 to 3 mg/kg dIV and maintained a plasma concentration of 150 to 200 U/L to prevent GVHD, and concurrent GVHD to MP 2 mg/kg d. The second group of 114 patients, the median age of 35 years old, including 26 cases of ALL, 33 cases of AML, 27 cases of CML, 30 cases of other hematological malignancies. Patients receive an enhancement regimen: CsA 5ng/kg·d IV (when serum is not present)